8 research outputs found
BARIS: A phase I trial to evaluate the safety and tolerability of combined BIBF 1120 mid RAD001 in stolid tumors and to determine the maximum tolerated dose (MTD) of the combination.
No full textBARIS: A phase I trial to evaluate the safety and tolerability of combined BIBF 1120 and RAD001 in solid tumors and to determine the maximum tolerated dose (MTD) of the combination.
No full textTRY: A phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutation.
No full textMIMEB: A phase II trial to evaluate FDG-PET/FLT-PET, DCE-MRI and molecular biomarkers for early prediction of nonprogression in patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab.
No full textClinical and molecular characteristics of non-small cell lung cancer patients harboring PIK3CA mutations.
No full textTRY: A phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutation.
No full text
